Annual Accounts Payable
$2.46 M
+$1.96 M+386.00%
31 December 2023
Summary:
Verrica Pharmaceuticals annual accounts payable is currently $2.46 million, with the most recent change of +$1.96 million (+386.00%) on 31 December 2023. During the last 3 years, it has risen by +$2.12 million (+608.05%). VRCA annual accounts payable is now at all-time high.VRCA Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$966.00 K
-$184.00 K-16.00%
30 September 2024
Summary:
Verrica Pharmaceuticals quarterly accounts payable is currently $966.00 thousand, with the most recent change of -$184.00 thousand (-16.00%) on 30 September 2024. Over the past year, it has dropped by -$959.00 thousand (-49.82%). VRCA quarterly accounts payable is now -61.77% below its all-time high of $2.53 million, reached on 31 March 2024.VRCA Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRCA Accounts Payable Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +386.0% | -49.8% |
3 y3 years | +608.0% | +6.9% |
5 y5 years | +156.7% | -4.4% |
VRCA Accounts Payable High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | at high | +608.0% | -61.8% | +605.1% |
5 y | 5 years | at high | +608.0% | -61.8% | +605.1% |
alltime | all time | at high | +2292.2% | -61.8% | +605.1% |
Verrica Pharmaceuticals Accounts Payable History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | $966.00 K(-16.0%) |
June 2024 | - | $1.15 M(-54.5%) |
Mar 2024 | - | $2.53 M(+2.6%) |
Dec 2023 | $2.46 M(+386.0%) | $2.46 M(+28.0%) |
Sept 2023 | - | $1.93 M(-6.4%) |
June 2023 | - | $2.06 M(+257.7%) |
Mar 2023 | - | $575.00 K(+13.4%) |
Dec 2022 | $507.00 K(-40.0%) | $507.00 K(+270.1%) |
Sept 2022 | - | $137.00 K(-80.8%) |
June 2022 | - | $714.00 K(+34.5%) |
Mar 2022 | - | $531.00 K(-37.2%) |
Dec 2021 | $845.00 K | $845.00 K(-6.5%) |
Sept 2021 | - | $904.00 K(+15.5%) |
June 2021 | - | $783.00 K(-10.8%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2021 | - | $878.00 K(+152.3%) |
Dec 2020 | $348.00 K(-70.6%) | $348.00 K(+94.4%) |
Sept 2020 | - | $179.00 K(-86.2%) |
June 2020 | - | $1.30 M(+17.6%) |
Mar 2020 | - | $1.10 M(-6.9%) |
Dec 2019 | $1.19 M(+23.4%) | $1.19 M(+17.3%) |
Sept 2019 | - | $1.01 M(-31.4%) |
June 2019 | - | $1.47 M(+29.7%) |
Mar 2019 | - | $1.14 M(+18.3%) |
Dec 2018 | $960.00 K(+474.9%) | $960.00 K(-13.1%) |
Sept 2018 | - | $1.10 M(-1.1%) |
June 2018 | - | $1.12 M(+80.7%) |
Mar 2018 | - | $618.00 K(+270.1%) |
Dec 2017 | $167.00 K(+62.1%) | $167.00 K |
Dec 2016 | $103.00 K | - |
FAQ
- What is Verrica Pharmaceuticals annual accounts payable?
- What is the all time high annual accounts payable for Verrica Pharmaceuticals?
- What is Verrica Pharmaceuticals annual accounts payable year-on-year change?
- What is Verrica Pharmaceuticals quarterly accounts payable?
- What is the all time high quarterly accounts payable for Verrica Pharmaceuticals?
- What is Verrica Pharmaceuticals quarterly accounts payable year-on-year change?
What is Verrica Pharmaceuticals annual accounts payable?
The current annual accounts payable of VRCA is $2.46 M
What is the all time high annual accounts payable for Verrica Pharmaceuticals?
Verrica Pharmaceuticals all-time high annual accounts payable is $2.46 M
What is Verrica Pharmaceuticals annual accounts payable year-on-year change?
Over the past year, VRCA annual accounts payable has changed by +$1.96 M (+386.00%)
What is Verrica Pharmaceuticals quarterly accounts payable?
The current quarterly accounts payable of VRCA is $966.00 K
What is the all time high quarterly accounts payable for Verrica Pharmaceuticals?
Verrica Pharmaceuticals all-time high quarterly accounts payable is $2.53 M
What is Verrica Pharmaceuticals quarterly accounts payable year-on-year change?
Over the past year, VRCA quarterly accounts payable has changed by -$959.00 K (-49.82%)